A scoping review published online on 11 August 2026 in The American Journal of Sports Medicine takes a systematic look at the evidence behind six of the most discussed research peptides and related compounds: BPC-157, TB-500 (thymosin beta-4), CJC-1295, ipamorelin, GHK-Cu and the non-peptide secretagogue MK-677. The authors, an orthopaedic surgery team at the David Geffen School of Medicine at UCLA, set out to answer a question the research peptides field rarely gets asked in one place: what does the peer-reviewed record actually show for these compounds in musculoskeletal models?

The timing matters. As the reviewers note in their background, the peptide supplement market has grown rapidly on marketing claims of enhanced performance and faster recovery, and these compounds are, in their words, often perceived as low risk despite the absence of efficacy or safety data for many of them. A structured evidence map from an academic orthopaedics group is therefore useful reading on both sides of the laboratory door.

How the review was built

The team followed PRISMA guidelines for a scoping review. They searched PubMed using permutations of the six compound names combined with seven musculoskeletal tissue terms: bone, fracture, muscle, tendon, ligament, meniscus and cartilage. Two reviewers screened every paper independently, with a third acting as tiebreaker. Studies qualified if they examined any of the compounds for musculoskeletal treatment, tissue recovery or performance, in animal or human models.

What the reviewers found

The evidence base is mostly preclinical. Overall, 67 percent of the identified publications used animal models, most commonly rats.
Mechanisms are distinct, effects are variable. In animal models, the authors report that each compound showed unique mechanisms with promising but variable effects on tendon, muscle, bone and ligament healing.
Human data are thin. Human clinical studies were limited to a handful of investigations, most lacking robust controls or rigorous designs. The authors describe the human data as heterogeneous, with modest improvements at best, confined to metabolic bone health and degenerative knee pain.
Methods vary widely. The review flags significant heterogeneity in dosing and route of administration across the published studies, which limits comparability.
Risks are documented. The authors highlight cardiovascular complications, including an association between MK-677 and congestive heart failure, and metabolic dysfunction such as insulin resistance.

The conclusion is direct: despite promising findings in animal studies, the claimed benefits of emerging peptide supplements for musculoskeletal recovery and performance remain unsubstantiated by current human trials, and the authors state that such supplements should not currently be recommended as a replacement or adjunct for existing orthopaedic standard of care.

Compound notes for research peptide buyers

Five of the six compounds in the review are available in our catalog as research reagents, each with its own documentation:

BPC-157: the most studied of the group in preclinical injury models; the review places nearly all of its musculoskeletal evidence in animal work.
TB-500: the synthetic form of thymosin beta-4, examined by the reviewers across skin, tendon and muscle repair models, again primarily preclinical.
GHK-Cu: the copper-binding tripeptide, included by the reviewers for its tissue-remodelling signals in laboratory models.
CJC-1295 and Ipamorelin: growth-hormone-axis research tools whose musculoskeletal endpoints the review traces through the GH and IGF-1 literature.
MK-677 (ibutamoren): a non-peptide secretagogue the reviewers included alongside the peptides. It carries the review’s clearest risk signal, the reported association with congestive heart failure. It is not part of our catalog.

What this means for laboratory research

Read as a research agenda, the review is a map of gaps. Standardised animal models, controlled designs and consistent administration routes are largely missing from the published record, and that is precisely the work laboratories can take on. It is the same evidence-first logic behind our own evidence-tier ranking of research peptides, which weighs replication and study quality rather than popularity.

For sourcing, the practical lesson is about documentation rather than claims: a compound with a verifiable certificate of analysis for the specific batch is a usable research input, whatever the state of the clinical literature. Our guide on how to read a certificate of analysis covers what that documentation should contain. Nothing in this review changes the regulatory status of these compounds: they remain research use only.

What a scoping review can and cannot tell you

A scoping review maps the breadth of a literature; it does not weigh it. The UCLA team did not run a meta-analysis, so the paper produces no pooled effect sizes and no statistical verdict on any single compound or mechanism. What it produces is a census: how many studies exist, in which models, on which tissues, and with what quality of design. That census is exactly what was missing from a field where individual animal studies are often quoted as if they settled the question.

For readers following the field, three signals are worth watching from here: registered clinical trials on these compounds appearing on ClinicalTrials.gov, replication of the animal findings by laboratories independent of the original groups, and any move toward standardised models and administration routes that would make future studies comparable. These are the same criteria our quarterly evidence review applies when tier assignments are updated. None of these signals require taking a position today; they only require watching the record as it grows.

References

Tewari K, Liu TP, Im C, Hamad C, Petrigliano F, Cheung EC, Kremen TJ Jr. Peptide Supplements and Their Therapeutic Applications in Sports Medicine. The American Journal of Sports Medicine, online ahead of print, 11 August 2026. PubMed record
Publisher version of record: doi.org/10.1177/03635465261464420
PRISMA reporting guidelines: prisma-statement.org

The products referenced on this site are supplied for laboratory research use only. They are not medicines and are not intended for human or veterinary use. This article summarises published research for informational purposes and is not medical advice. Statements about third-party studies belong to their authors.